Manon Boisclair

CEO & Founder, InnovID B2 | MS, MBA, ICD.D

Role: Associate

Sites: CDL-Montreal, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Streams: Artificial Intelligence, Cancer, Health & Wellness

Manon Boisclair is a Canadian-American entrepreneur and founder of InnovID B2, a boutique firm in impact consulting in life science and sustainability. She has over 20 years of international experience in executive management roles with NASDAQ-listed biopharma companies (Merck, Novartis, Celgene and Intercept) in the US, Canada and Europe. She has extensive global operations, go-to-market medical/marketing strategy expertise, launched several oncology blockbusters, and worked on early pipeline compounds in rare diseases and NASH.

Involved in private equity, Manon is a limited partner with Accelia Capital and an advisor to venture capital firms in life sciences. She is also a seasoned angel investor with a solid track record in business development, governance, and Series A & B fundraising. Manon is a board director of PE companies as well as on the governance committee of the Canadian Cancer Society.

Active in the startup ecosystem, she is a mentor to several entrepreneurs affiliated with Creative Destruction Lab, Centech, CTS and District3. Manon fosters trailblazing entrepreneurs who are laser-focused on the rapid scaling of their solutions. She is a healthcare clinician with a master’s from the University of Montreal and an executive MBA from McGill/HEC Montreal. In addition, Manon is a certified corporate board director from Harvard Business School, the Institute of Corporate Directors and obtained an ESG designation from Competent Boards.